|
1
|
Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer.
|
J Clin Oncol
|
2007
|
11.04
|
|
2
|
Phase III trial of bevacizumab in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer.
|
J Clin Oncol
|
2009
|
3.61
|
|
3
|
Amphiregulin and epiregulin mRNA expression in primary tumors predicts outcome in metastatic colorectal cancer treated with cetuximab.
|
J Clin Oncol
|
2009
|
2.92
|
|
4
|
Phase II trial of cetuximab in combination with fluorouracil, leucovorin, and oxaliplatin in the first-line treatment of metastatic colorectal cancer.
|
J Clin Oncol
|
2007
|
2.47
|
|
5
|
Massively parallel tumor multigene sequencing to evaluate response to panitumumab in a randomized phase III study of metastatic colorectal cancer.
|
Clin Cancer Res
|
2013
|
2.03
|
|
6
|
Clinical usefulness of EGFR gene copy number as a predictive marker in colorectal cancer patients treated with cetuximab: a fluorescent in situ hybridization study.
|
Clin Cancer Res
|
2008
|
1.80
|
|
7
|
Levels of gemcitabine transport and metabolism proteins predict survival times of patients treated with gemcitabine for pancreatic adenocarcinoma.
|
Gastroenterology
|
2012
|
1.67
|
|
8
|
Human equilibrative nucleoside transporter 1 and human concentrative nucleoside transporter 3 predict survival after adjuvant gemcitabine therapy in resected pancreatic adenocarcinoma.
|
Clin Cancer Res
|
2009
|
1.62
|
|
9
|
Phase III trial comparing protracted intravenous fluorouracil infusion alone or with yttrium-90 resin microspheres radioembolization for liver-limited metastatic colorectal cancer refractory to standard chemotherapy.
|
J Clin Oncol
|
2010
|
1.61
|
|
10
|
Endogenous interleukin-10 modulates fibrosis and regeneration in experimental chronic pancreatitis.
|
Am J Physiol Gastrointest Liver Physiol
|
2002
|
1.20
|
|
11
|
Epidermal growth factor receptor and K-RAS status in two cohorts of squamous cell carcinomas.
|
BMC Cancer
|
2010
|
1.10
|
|
12
|
Deoxycitidine kinase is associated with prolonged survival after adjuvant gemcitabine for resected pancreatic adenocarcinoma.
|
Cancer
|
2010
|
1.09
|
|
13
|
Anti-epidermal growth factor receptor monotherapy in the treatment of metastatic colorectal cancer: where are we today?
|
Oncologist
|
2009
|
1.05
|
|
14
|
Putative contribution of CD56 positive cells in cetuximab treatment efficacy in first-line metastatic colorectal cancer patients.
|
BMC Cancer
|
2010
|
0.98
|
|
15
|
Tolerance and efficacy of gemcitabine and gemcitabine-based regimens in elderly patients with advanced pancreatic cancer.
|
Pancreas
|
2008
|
0.91
|
|
16
|
Cetuximab in combination with irinotecan/5-fluorouracil/folinic acid (FOLFIRI) in the initial treatment of metastatic colorectal cancer: a multicentre two-part phase I/II study.
|
BMC Cancer
|
2009
|
0.90
|
|
17
|
Docetaxel plus gemcitabine or docetaxel plus cisplatin in advanced pancreatic carcinoma: randomized phase II study 40984 of the European Organisation for Research and Treatment of Cancer Gastrointestinal Group.
|
J Clin Oncol
|
2005
|
0.87
|
|
18
|
Correlation between the response to cetuximab alone or in combination with irinotecan and the activated/phosphorylated epidermal growth factor receptor in metastatic colorectal cancer.
|
Semin Oncol
|
2005
|
0.84
|
|
19
|
Argon plasma coagulation in Barrett's esophagus.
|
Gastrointest Endosc Clin N Am
|
2003
|
0.83
|
|
20
|
Adjuvant gemcitabine and concurrent continuous radiation (45 Gy) for resected pancreatic head carcinoma: a multicenter Belgian Phase II study.
|
Int J Radiat Oncol Biol Phys
|
2005
|
0.83
|
|
21
|
Clinical Benefit and Health-Related Quality of Life Assessment in Patients Treated with Cisplatin/S-1 Versus Cisplatin/5-FU: Secondary End Point Results From the First-Line Advanced Gastric Cancer Study (FLAGS).
|
J Gastrointest Cancer
|
2015
|
0.81
|
|
22
|
S100A2 is a predictive biomarker of adjuvant therapy benefit in pancreatic adenocarcinoma.
|
Eur J Cancer
|
2013
|
0.81
|
|
23
|
Adjuvant pharmacotherapy in the management of elderly patients with pancreatic cancer.
|
Drugs Aging
|
2013
|
0.79
|
|
24
|
Adjuvant chemotherapy for colorectal cancer.
|
Curr Gastroenterol Rep
|
2002
|
0.79
|
|
25
|
Predictive factors for survival in patients with inoperable Klatskin tumors.
|
Hepatogastroenterology
|
2006
|
0.78
|
|
26
|
HuR modulates gemcitabine efficacy: new perspectives in pancreatic cancer treatment.
|
Expert Rev Anticancer Ther
|
2009
|
0.77
|
|
27
|
Treatment of pancreatic cancer: what can we really predict today?
|
Cancers (Basel)
|
2011
|
0.76
|
|
28
|
Exploring limits for data registration in the context of PROCARE, a quality improvement project on rectal cancer.
|
Acta Chir Belg
|
2012
|
0.75
|
|
29
|
Feasibility of Immunohistochemistry on Endoscopic Ultrasound Fine-Needle Aspiration Samples for Evaluating Predictive Biomarkers in Pancreatic Cancer Management.
|
Pancreas
|
2016
|
0.75
|
|
30
|
Endoscopic fluorescence detection of low and high grade dysplasia in Barrett's oesophagus using systemic or local 5-aminolaevulinic acid sensitization.
|
Gastrointest Endosc
|
2002
|
0.75
|
|
31
|
Squamous cell carcinoma of the esophagus: multimodal therapy in locally advanced disease.
|
World J Surg
|
2001
|
0.75
|
|
32
|
The multidisciplinary management of gastrointestinal cancer. Biliary tract cancers: from pathogenesis to endoscopic treatment.
|
Best Pract Res Clin Gastroenterol
|
2007
|
0.75
|
|
33
|
Towards a tailored therapy in pancreatic cancer.
|
Acta Gastroenterol Belg
|
2013
|
0.75
|